Envenomation by the snake Bothrops jararaca is typically associated with hemostatic abnormalities including pro- and anticoagulant disturbances. Glycyrrhizin (GL) is a plant-derived thrombin inhibitor that also exhibits in vivo antithrombotic properties. Here, we evaluated the ability of GL to counteract the hemostatic abnormalities promoted by B. jararaca venom. GL inhibited the human fibrinogen clotting (IC50=∼1.0 mg ml−1; 1.2 mM), H-D-phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide dihydrochloride hydrolysis (IC50=∼0.4 mg ml−1; 0.47 mM) and platelet aggregation (IC50=∼0.28 mg ml−1; 0.33 mM) induced by B. jararaca venom, in vitro. The in vivo effect of GL was tested in rats using a model of venous thrombosis in which intravenous (i.v.) administration of B. jararaca venom (100 μg kg−1) produced in all animals a thrombus with a mean weight of 10.6±1.7 mg. Prior administration of GL (180 mg kg−1) or antibothropic serum (27 μl kg−1) inhibited thrombus formation by 86 and 67%, respectively. Remarkably, co-administration of ineffective doses of GL and antibothropic serum markedly decreased thrombus weight, suggesting a synergistic effect. Co-administration of GL with antibothropic serum abolished venom-induced bleeding. Ex vivo clotting times showed that rat plasma was non-clotting after i.v. administration of B. jararaca venom. Treatment with GL, antibothropic serum or both before venom administration efficiently prevented this abnormality. Altogether, we demonstrate here that GL prevents both in vitro and in vivo venom-induced changes in hemostasis, suggesting a potential antiophidic activity. Keywords: Glycyrrhizin, B. jararaca venom, venous thrombosis, antibothropic serum Introduction In Brazil, snakebite accidents represent an important public health problem, with the genus Bothrops (including the species B. jararaca, B. moojeni, B. erythromelas and B. atrox) being responsible for more than 90% of the registered cases (Cardoso, 1990). A number of proteins from bothropic venoms interfere with the hemostatic system and have been characterized in detail (Markland, 1998; Castro et al., 2004) as procoagulant, anticoagulant or fibrinolytic factors (Marsh, 1994). In addition, several components may alter platelet function displaying either pro- or antiaggregating properties (Markland, 1998). The signs and symptoms presented by patients include local (pain, swelling, ecchymosis and necrosis) and systemic (blood incoagulability, hemorrhage) manifestations (Kamiguti et al., 1986; Maruyama et al., 1990). Envenomation by these snakes generally results in strong coagulopathy with persistent bleeding owing to fibrinogen degradation as well as consumption of blood coagulation factors (Maruyama et al., 1990; Kamiguti et al., 1991). On the other hand, massive blood clotting activation may cause thrombosis in small vessels (Thomas et al., 1995). Therefore, severe cases of envenomotion may lead to permanent tissue loss, disability or amputation. The effective therapeutic treatment for ophidian accidents nowadays is serotherapy (Heard et al., 1999). Nevertheless, alternative medication has been proposed. The use of heparin was first proposed in the late 40s (Ahuja et al., 1946). Although it is a well-known anticoagulant, heparin does not neutralize the thrombin-like activity of bothropic venoms and does not prevent the defibrinogenating syndrome induced by these venoms (Nahas et al., 1975). In fact, structural differences between thrombin and venom-derived thrombin-like enzymes impair the inhibitory action of heparin–antithrombin complex as well as other coagulation inhibitors such as hirudin (Castro et al., 2004). A number of studies have also reported the use of plants (or their extracts) known in popular medicine for treatment of snakebite (Mors et al., 1989; 2000; Mors, 1991; Martz, 1992; Houghton & Osibogun, 1993; Houghton & Skari, 1994). Among these studies, some focus on the inhibition of snake venom hemostatic effects. Extracts from plants widely used in India, Sri Lanka and West Africa showed significant dose-related prolongation of Echis carinatus venom-induced clot formation in human plasma (Onuaguluchi & Okeke, 1989). It has also been shown that the extract of the Brazilian plant Marsypianthes chamaedrys inhibits fibrinogen clotting induced by several Brazilian snake venoms, indicating that it affects thrombin-like enzymes (Castro et al., 2003). Glycyrrhizin (GL) is a natural triterpenoid saponin extracted from the root of a Legumisosae, Glycyrrhiza glabra (licorice), with a molecular mass of 840 Da. This compound is known for its anti-inflammatory activity (Fogden & Neuberger, 2003) and has been also characterized as a thrombin inhibitor (Francischetti et al., 1997). Thrombin, which plays a central role in the hemostatic system, displays very high specificity upon a small range of substrates. This is particularly attributed to the presence of two positively charged regions that are located at a distance from its catalytic site, named ‘anion-binding exosites', which play major roles in the recognition of substrates and inhibitors (Stubbs & Bode, 1995). In fact, it was demonstrated that GL binds to thrombin exosite 1 and blocks the enzyme action upon fibrinogen and platelets (Francischetti et al., 1997), displaying a similar mechanism to that described for the C-terminal hirudin-based non-apeptide (Krstenansky & Mao, 1987). Further studies demonstrated that GL has in vivo antithrombotic properties (Mendes-Silva et al., 2003). Based on the known coagulopathy state generated by the envenomation, we attempted to evaluate the ability of GL to counteract this condition caused by B. jararaca venom. For this purpose, we injected crude venom intravenously in rats and measured thrombus formation, ex vivo clotting times and bleeding effect. GL was effective both in vitro and in vivo. Also, GL showed a synergistic effect when combined with antibothropic serum. Our data indicate that in vitro experiments combined with the animal model herein described would be useful to evaluate compounds with potential ability to reduce the venom-induced hemostatic abnormalities.